Antifungal susceptibility, FKS1 gene expression, and virulence determinants of Candida albicans in pediatric and neonatal candidiasis Authors: Mandana Rezaei-Mojaz, Hanie Hajghafari, Masoomeh Shams-Ghahfarokhi, Simasadat Seyedjavadi, Zahra Salehi, Ali Eslamifar, Fatemehsadat Jamzivar, Mehdi Razzaghi-Abyaneh Published: 2026 ABSTRACT AbstractBackgroundCandida albicans is a major cause of invasive fungal infections in pediatric patients, including subgroups of neonates and young infants, particularly in intensive care settings where premature and low birth weight infants are at high risk. Management is increasingly complicated by antifungal resistance, notably to echinocandins. Understanding basal FKS1 expression, antifungal susceptibility, and virulence traits in neonatal isolates, as a subgroup within pediatric patients, provides preliminary insights for clinical management.MethodsA cross-sectional study was conducted on pediatric patients with suspected fungal infections admitted to NICU, PICU, IICU, and other specialized wards of the Children’s Medical Center, Tehran, Iran. Clinical specimens were collected from multiple sources including urine catheters, blood, abscesses, bronchoalveolar lavage, and other body fluids. Of 62 Candida isolates recovered, 50 (80.6%) were identified as C. albicans. For detailed molecular, antifungal susceptibility, enzymatic virulence, and FKS1 expression analyses, 20 isolates from children under two years of age (7 newborns and 13 infants) were selected. Species identification was confirmed by ITS sequencing. Antifungal susceptibility testing followed CLSI M27-A4 documents with MICs determined based on 50% growth inhibition. Virulence was assessed via phospholipase and proteinase enzymatic activity, and FKS1 gene expression was measured using real-time PCR.ResultsAll 50 analyzed isolates were confirmed as C. albicans with > 99% ITS sequence identity. Phylogenetic analysis revealed strong genetic relatedness among isolates. Caspofungin and amphotericin B demonstrated the highest in vitro efficacy, with 44 isolates (88%) susceptible to caspofungin and 27 isolates (54%) susceptible to amphotericin B. Resistance to fluconazole and ketoconazole was observed in 28 (56%) and 33 (66%) isolates, respectively. Virulence profiling showed that a subset of pediatric isolates, including neonatal cases, exhibited strong phospholipase and proteinase activity, suggesting elevated pathogenic potential within this subgroup. FKS1 was detected in all isolates, with expression levels varying significantly; notably, two neonatal isolates showed higher basal FKS1 expression, potentially indicating early adaptive responses to echinocandin exposure despite phenotypic susceptibility. All subsequent analyses, including molecular and functional assays, explicitly indicate the number of isolates evaluated for each experiment, ensuring clarity and reproducibility.ConclusionThis study highlights the multifactorial pathogenicity of C. albicans in pediatric patients, with exploratory observations in neonates and young infants characterized by variable antifungal resistance and virulence factor expression. Variations in basal FKS1 expression are described as preliminary findings. These data underscore the value of integrating molecular diagnostics, antifungal susceptibility testing, and virulence profiling to guide therapy, without making unsupported claims about echinocandin tolerance.Keywords: Candida albicans, Pediatric candidiasis, Neonatal subgroup, FKS1 gene expression, Antifungal resistance, Pathogenicity, Virulence factors Introduction Candidiasis continues to be a major opportunistic fungal infection in humans, posing a significant threat especially to individuals with weakened immune systems, including hospitalized patients [1]. Among the various Candida species, C. albicans remains the most commonly isolated and is responsible for a broad spectrum of infections, ranging from mild mucosal conditions to severe, invasive disease [2]. Its success as a pathogen is supported by several well-recognized virulence traits, including adherence to host tissues, secretion of hydrolytic enzymes, morphological flexibility, and the ability to form biofilms, all of which enhance colonization and allow the organism to evade immune defenses [3]. Although invasive candidiasis can affect children of any age, neonates, especially premature and low birth weight infants, represent one of the most vulnerable groups. Their immature immune system, long hospital stays, and frequent exposure to invasive procedures or broad-spectrum antibiotics place them at a considerably higher risk [4–6]. At the same time, candidiasis is not limited to this early period of life, and older children may develop invasive infections due to underlying medical conditions or intensive care exposure [7]. For this reason, pediatric studies commonly include a wider age range even when neonates form a clinically important subgroup. The growing use of antifungal agents in pediatric care, most notably azoles and echinocandins, has contributed to the emergence of drug-resistant Candida strains [8]. Azole resistance is relatively common, whereas echinocandin resistance remains less frequent but is clinically meaningful because agents such as caspofungin are often used to treat invasive disease in critically ill infants and children [9]. Resistance to echinocandins is mainly associated with mutations in specific regions of the FKS genes, particularly FKS1, which encodes a key component of the beta-1,3-glucan synthase complex involved in fungal cell wall synthesis [10–12]. In addition to such mutations, increased expression of FKS1 has been suggested as part of an adaptive stress response that may affect drug susceptibility even when routine phenotypic testing does not show resistance [13]. Given this background, a clearer understanding of antifungal susceptibility patterns, virulence-related enzyme activity, and exploratory FKS1 gene expression in pediatric C. albicans isolates, from a pediatric cohort, with a specific exploratory focus on neonates and infants under two years of age, can provide valuable descriptive insights to support clinical awareness and future research. In this study, we examined C. albicans isolates obtained from a pediatric cohort with a focus on neonates. We evaluated antifungal susceptibility, characterized hydrolytic enzyme activity, and measured FKS1 expression, presenting observed differences as preliminary findings without inferring phenotypic echinocandin resistance. Methods Study population and clinical isolates collection This cross-sectional study was conducted at the Children’s Medical Center, affiliated with Tehran University of Medical Sciences, and included pediatric patients admitted to units such as the NICU, PICU, IICU, and other specialized wards. Children were enrolled based on clinical suspicion of systemic fungal infection, assessed by a pediatric infectious disease specialist. A combination of clinical findings, laboratory parameters, imaging results and response to empirical antifungal therapy was used to support the diagnosis. Demographic and clinical characteristics of pediatric patients with fungal infections are shown in Table 1. Table 1Demographic and clinical characteristics of pediatric patients with fungal infectionsParameterCategoryNumber (n = 50)Percentage (%)GenderMale2856Female2244Marital StatusSingle50100Age GroupNewborn – 1 month7142 months – 1 year13262–5 years10206–10 years81611–15 years81616–19 years48Underlying DiseaseCystic Fibrosis (CF)510Congenital Heart Disease (including VSD-ASD, CHD, cardiac surgeries)714Immunodeficiency48Sepsis36Down Syndrome36Other (metabolic disorders, neurological diseases, MSUD, cancers, hydrocephalus, osteomyelitis, respiratory distress, etc.)2856Sampling TypeUrine catheter (UC)1836Blood culture (BC)918Abscess drainage36Bronchoalveolar lavage (BAL)24Catheter tip12Central venous line (CV LINE)12Throat swab24Other (pleural fluid, ascitic fluid, wound swabs, tracheal secretions, nasal secretions, vaginal swabs)1428Hospital WardNICU / IICU1122PICU510Outpatient (OP)612Emergency room (ER)36Infectious diseases ward48Surgery-related wards48EICU24Other specialized wards1530Mortality StatusDeceased1020Alive4080Antifungal Treatment AdministeredYes4896No24 Demographic and clinical characteristics of pediatric patients with fungal infections During the study period, 62 Candida isolates were recovered from eligible patients. Species identification showed that 50 isolates were C. albicans and 12 isolates were Candida glabrata. Only C. albicans isolates were included in further analyses because the primary focus of the study was early-life C. albicans pathogenicity and antifungal response. Among the 50 C. albicans isolates, 20 isolates were obtained from children younger than two years of age, including seven newborns to one month old and thirteen infants aged two months to one year. These 20 isolates were selected for molecular identification through ITS sequencing, virulence enzyme assays and FKS1 gene expression analysis. Specimens originated from urine catheters, blood cultures, abscess drainages, BAL samples, catheter tips, central venous lines, throat swabs and other clinical sources such as pleural fluid, ascitic fluid, wound swabs, tracheal secretions, nasal swabs and vaginal swabs. The study received approval from the Ethics Committee of Tehran Medical Sciences Islamic Azad University (Approval No. IR.IAU.PS.332). Written informed consent was obtained from parents or legal guardians. Transport and initial microbiological processing All clinical specimens were promptly transferred to the Mycology Laboratory of the Pasteur Institute of Iran under cold chain conditions and standard biosafety protocols. Upon arrival, isolates were immediately processed for culture and phenotypic characterization. Each specimen was inoculated onto Sabouraud dextrose agar (SDA, Merck, Darmstadt, Germany) supplemented with chloramphenicol and incubated at 35–37 °C for 24 to 72 h [14]. Isolates were preliminarily identified based on colony morphology, with colonies typically appearing white to cream-colored, smooth or slightly wrinkled, moist, and exhibiting well-defined margins. Microscopic evaluation was performed using a 10% potassium hydroxide (KOH) preparation to observe oval yeast cells (blastoconidia) and, where present, pseudohypha elements. These characteristics were used as initial indicators of Candida spp [15]. Molecular identification via ITS region amplification Species-level identification was achieved through amplification of the internal transcribed spacer (ITS) region of fungal rDNA using universal primers ITS1 (5′-TCCGTAGGTGAACCTGCGG-3′) and ITS4 (5′-TCCTCCGCTTATTGATATGC-3′) [16]. PCR reactions were performed in a 25.1 µL volume containing 12.5 µL of 2X PCR Master Mix (Ampliqon, Denmark), 0.3 µL of each primer, 1 µL of genomic DNA, and 11 µL of nuclease-free water. Thermal cycling was conducted using the following program: initial denaturation at 95 °C for 5 min; 40 cycles of denaturation at 94 °C for 45 s, annealing at 60 °C for 30 s, and extension at 72 °C for 1 min; followed by a final extension at 72 °C for 7 min. Amplicons (expected size: 500–600 bp) were visualized via electrophoresis on 1% agarose gels stained with GelRed (Biotium, USA). Sequencing and phylogenetic analysis PCR products were purified using the Yekta Tajhiz Azma DNA Purification Kit, Iran and subjected to Sanger sequencing using the ABI 3730xl DNA Analyzer (Applied Biosystems, USA) with BigDye Terminator v3.1 chemistry. Sequencing was performed in both forward and reverse directions with a read length of approximately 700 base pairs. The primer sequences used were ITS1 and ITS4. Raw sequence chromatograms were assessed using Chromas (Technelysium Pty Ltd, Australia) and MEGA version 7 for quality control and editing. Species identification was determined via BLASTn searches against the NCBI GenBank database. A match of ≥ 99% sequence identity, combined with acceptable E-values and query coverage, was considered conclusive for species confirmation. Multiple sequence alignments were performed using the ClustalW algorithm implemented in MEGA 7. A neighbor-joining phylogenetic tree was constructed using the Kimura 2-parameter model with 1,000 bootstrap replications. Clusters with bootstrap values > 70% were interpreted as statistically robust and reflective of reliable phylogenetic relationships among isolates and reference Candida strains. Antifungal susceptibility testing The in vitro antifungal susceptibility of the Candida isolates was evaluated using the broth microdilution method according to the Clinical and Laboratory Standards Institute (CLSI) M27-A4 document [17]. The antifungal agents tested included amphotericin B, fluconazole, voriconazole, itraconazole, ketoconazole, and caspofungin. Minimum inhibitory concentration (MIC) endpoints were determined with azole and echinocandin MICs read at approximately 50% inhibition, and amphotericin B MICs read at 100% inhibition. Interpretive categories for fluconazole, voriconazole, amphotericin B, and caspofungin were assigned using the most recent CLSI clinical breakpoints (CBPs), whereas MIC data for itraconazole and ketoconazole, which lack established CBPs, were interpreted using the latest epidemiological cutoff values (ECVs) to distinguish wild-type (WT) from non-wild-type (non-WT) phenotypes. Quantitative real-time PCR for FKS1 gene expression Quantitative real-time PCR (qRT-PCR) was performed to assess the expression of the FKS1 gene, a key molecular target associated with echinocandin resistance in C. albicans [18]. Total RNA was extracted from fresh fungal biomass using the RNX-Plus RNA extraction kit (CinnaGen, Iran), following the manufacturers protocol. RNA purity was evaluated using a NanoDrop spectrophotometer, ensuring A260/A280 ratios between 1.6 and 2.0, and RNA integrity was further confirmed by agarose gel electrophoresis. First-strand complementary DNA (cDNA) synthesis was performed using a commercial reverse transcription kit (Yekta Tajhiz Azma, Iran) with random hexamer primers and 1–2 µg of total RNA, following standardized thermal cycling conditions. Gene expression analysis was conducted using a SYBR Green-based qPCR assay on the CFX96 Real-Time PCR Detection System (Bio-Rad, USA). Each 13 µL reaction contained SYBR Green Master Mix, cDNA template, nuclease-free water, and 0.3 µM of forward and reverse primers specific for the target and reference genes. The primers used were as follows: FKS1 forward 5′-GGATATCAAGACCAAGCCAACTA-3′, FKS1 reverse 5′-CCAGGAGTTTGACCACCATAA-3′, ACT1 forward 5′-ACTACCATGTTCCCAGGTATTG − 3′, and ACT1 reverse 5′-CCACCAATCCAGACAGAGTATT-3′. Amplification was performed in biological duplicates for both resistant and susceptible isolates, with thermal cycling consisting of an initial denaturation at 95 °C for 3 min, followed by 40 cycles of 95 °C for 10 s and 60 °C for 30 s, and a melt curve analysis to confirm amplification specificity [19]. FKS1 expression was normalized to the internal reference gene ACT1 within each isolate, and relative expression levels were calculated using the 2−ΔΔCt method. Biological duplicates were performed for each isolate, and each reaction was run in technical duplicate. The resulting values reflect the intrinsic expression of FKS1 in each isolate rather than fold changes relative to a separate calibrator strain. This method allows the direct comparison of expression patterns across isolates, including both resistant and susceptible strains, without introducing external reference biases. Assessment of virulence-associated enzymatic activities The pathogenic potential of C. albicans isolates was evaluated through the production of extracellular enzymes using established phenotypic assays [20]. Proteinase activity was assessed on bovine serum albumin (BSA)-containing agar, following the method of Staib et al. with minor modifications. Each isolate was spot-inoculated onto the agar and incubated at 37 °C. Although standard protocols typically recommend 2–4 days of incubation, the plates were incubated for 5–7 days to allow complete visualization of hydrolysis zones, particularly for isolates exhibiting slower enzymatic activity. Proteolytic activity was quantified using the Pz index, defined as the ratio of the colony diameter to the total diameter including the clear zone of hydrolysis. Phospholipase activity was evaluated on egg yolk agar, consisting of Sabouraud dextrose agar supplemented with 1 M NaCl, 0.005 M CaCl₂, and 8% sterile egg yolk emulsion. Plates were incubated at 37 °C for 5–7 days, and the formation of precipitation zones surrounding the colonies was measured. Enzyme activity was quantified using the Pz index in the same manner as for proteinase. Enzymatic activity was categorized into four groups based on Pz values: strong (Pz < 0.69), moderate (0.70–0.89), weak (0.90–0.99), and negative (Pz = 1.0), as described by Price et al. These assays provided a standardized assessment of the virulence potential of the clinical C. albicans isolates, allowing comparison across isolates and correlation with antifungal susceptibility profiles. Statistical analysis Data were analyzed using appropriate statistical software (GraphPad Prism). MIC values, gene expression levels, and enzymatic activity data were expressed as means ± standard deviations (SD). Comparisons between groups (e.g., resistant vs. susceptible isolates) were evaluated using Student’s t-test or Mann–Whitney U test for non-normally distributed data. A p-value < 0.05 was considered statistically significant. Correlations between antifungal susceptibility, gene expression, and enzymatic activity were assessed using Spearman’s or Pearson’s correlation coefficients, as appropriate. Results PCR amplification and molecular identification of Candida isolates Amplification of the internal transcribed spacer (ITS) region was successfully achieved in all clinical Candida isolates. PCR products were visualized by electrophoresis on a 1% agarose gel stained with a DNA-binding fluorescent dye. All isolates yielded a single, well-defined band corresponding to an amplicon size of approximately 500–600 base pairs, consistent with the expected fragment size for the ITS region. The consistent amplification across isolates confirmed the integrity of extracted genomic DNA and the efficacy of ITS1 and ITS4 primers. Subsequent sequencing and BLAST analysis against the NCBI GenBank database revealed > 99% identity with C. albicans reference sequences, confirming species-level identification for all 20 clinical isolates. Phylogenetic analysis Phylogenetic analysis using the Neighbor-Joining method grouped all clinical isolates within the C. albicans clade. Bootstrap analysis demonstrated strong support values (≥ 95%), indicating genetic relatedness among isolates. Minor sequence variations were observed but did not influence overall species clustering, suggesting intra-species diversity among C. albicans isolates, including those from neonates as a subgroup of pediatric patients (Fig. 1). Phylogenetic analysis of Candida albicans isolates based on ITS1 and ITS4 sequences. The tree was constructed using the Neighbor-Joining method with the Kimura 2-parameter model and validated with 1,000 bootstrap replicates. Schizosaccharomyces cerevisiae NG-63,315 was used as the out-group. Branches with bootstrap values greater than 70% were considered well supported Antifungal susceptibility profiles Antifungal susceptibility testing was performed using the CLSI broth microdilution method (Tables 2 and 3). Caspofungin exhibited the highest efficacy, with 88% of isolates classified as susceptible and 12% showing resistance. Amphotericin B MICs ranged from 0.25 to 1 µg/mL, and all the isolates were considered susceptible according to CLSI M27-A4 clinical breakpoints (MICs ≤ 1 µg/mL), confirming consistent activity across the isolates. In contrast, a high proportion of isolates exhibited resistance to itraconazole (84%) and voriconazole (78%). Resistance to ketoconazole and fluconazole was observed in 66% and 56% of isolates, respectively. Table 2Antifungal susceptibility profiles of Candida albicans isolatesAntifungal drugSusceptible (No.)Resistant (No.)SDD/Intermediate (No.)Caspofungin4460Itraconazole8420Voriconazole11390Fluconazole20282Ketoconazole15332Amphotericin B5000 Antifungal susceptibility profiles of Candida albicans isolates Table 3Individual MIC values (µg/mL) and corresponding susceptibility interpretation for 50 Candida albicans isolatesIsolate No.CAS* (µg/mL)ITR (µg/mL)VOR (µg/mL)FLU (µg/mL)KTZ (µg/mL)AmpB (µg/mL)10.03S0.12WT0.03S0.25S0.12WT0.25WT20.06S0.25WT0.06S0.5S0.25WT0.5WT30.12S0.25non-WT0.12S1S0.25WT0.5WT40.25S0.5non-WT0.25S2S0.5non-WT1WT50.12S0.12WT0.06S0.5S0.25WT0.25WT60.03S0.25WT0.03S0.25S0.12WT0.25WT70.12S0.5non-WT0.12S4SDD0.25WT0.5WT80.25S0.25WT0.06S2S0.25WT0.5WT90.5R0.5non-WT0.25S8R0.5non-WT1WT100.06S0.12WT0.03S0.5S0.12WT0.25WT110.12S0.25WT0.12S2S0.25WT0.5WT120.25S0.5non-WT0.25S4SDD0.25WT0.5WT130.03S0.12WT0.03S0.25S0.12WT0.25WT140.06S0.25WT0.06S1S0.25WT0.5WT150.12S0.5non-WT0.12S2S0.25WT0.5WT160.25S0.25WT0.25I4SDD0.25WT0.5WT170.03S0.12WT0.03S0.5S0.12WT0.25WT180.06S0.25WT0.06S1S0.25WT0.5WT190.12S0.5non-WT0.12S2S0.25WT0.5WT200.25S0.25WT0.25I4SDD0.25WT0.5WT210.03S0.12WT0.03S0.25S0.12WT0.25WT220.12S0.25WT0.12S2S0.25WT0.5WT230.25S0.5non-WT0.25S4SDD0.25WT0.5WT240.03S0.12WT0.03S0.5S0.12WT0.25WT250.06S0.25WT0.06S1S0.25WT0.5WT260.12S0.5non-WT0.12S2S0.25WT0.5WT270.25S0.25WT0.25I4SDD0.25WT0.5WT280.03S0.12WT0.03S0.5S0.12WT0.25WT290.12S0.25WT0.12S2S0.25WT0.5WT300.25S0.5non-WT0.25S4SDD0.25WT0.5WT310.03S0.12WT0.03S0.5S0.12WT0.25WT320.12S0.25WT0.12S1S0.25WT0.5WT330.25S0.5non-WT0.25S2S0.25WT0.5WT340.03S0.12WT0.03S0.5S0.12WT0.25WT350.12S0.25WT0.12S1S0.25WT0.5WT360.25S0.5non-WT0.25S2S0.25WT0.5WT370.03S0.12WT0.03S0.5S0.12WT0.25WT380.12S0.25WT0.12S1S0.25WT0.5WT390.25S0.5non-WT0.25S2S0.25WT0.5WT400.03S0.12WT0.03S0.5S0.12WT0.25WT410.12S0.25WT0.12S1S0.25WT0.5WT420.25S0.5non-WT0.25S2S0.25WT0.5WT430.03S0.12WT0.03S0.5S0.12WT0.25WT440.12S0.25WT0.12S1S0.25WT0.5WT450.25S0.5non-WT0.25S2S0.25WT0.5WT460.03S0.12WT0.03S0.5S0.12WT0.25WT470.12S0.25WT0.12S1S0.25WT0.5WT480.25S0.5non-WT0.25S2S0.25WT0.5WT490.03S0.12WT0.03S0.5S0.12WT0.25WT500.12S0.25WT0.12S1S0.25WT0.5WT* MIC endpoints for azoles and caspofungin were determined at approximately 50% growth inhibition, while amphotericin B MICs were read at 100% inhibition, in accordance with CLSI M27-A4. Susceptibility categories were assigned using CLSI clinical breakpoints (CBPs), and for itraconazole and ketoconazole, epidemiological cutoff values (ECVs) were used to classify isolates as wild-type (WT) or non-wild-type (non-WT). CAS, Caspofungin; ITR, Itraconazole; VOR, Voriconazole; FLU, Fluconazole; KTZ, Ketoconazole; AmpB, Amphotericin B; S: susceptible; R: resistant; SDD: susceptible dose dependent; WT: wild type; non-WT: non-wild type Individual MIC values (µg/mL) and corresponding susceptibility interpretation for 50 Candida albicans isolates * MIC endpoints for azoles and caspofungin were determined at approximately 50% growth inhibition, while amphotericin B MICs were read at 100% inhibition, in accordance with CLSI M27-A4. Susceptibility categories were assigned using CLSI clinical breakpoints (CBPs), and for itraconazole and ketoconazole, epidemiological cutoff values (ECVs) were used to classify isolates as wild-type (WT) or non-wild-type (non-WT). CAS, Caspofungin; ITR, Itraconazole; VOR, Voriconazole; FLU, Fluconazole; KTZ, Ketoconazole; AmpB, Amphotericin B; S: susceptible; R: resistant; SDD: susceptible dose dependent; WT: wild type; non-WT: non-wild type In addition to categorical susceptibility results, MIC range, MIC50, and MIC90 values were calculated for each antifungal agent based on the individual MIC distributions shown in Tables 3 and 4. Caspofungin exhibited a MIC range of 0.03–0.5 µg/mL, with MIC50 and MIC90 values of 0.12 and 0.25 µg/mL, respectively. Itraconazole showed a MIC range of 0.12–0.5 µg/mL (MIC50 = 0.25 µg/mL; MIC90 = 0.5 µg/mL), while voriconazole ranged from 0.03 to 0.25 µg/mL (MIC50 = 0.12 µg/mL; MIC90 = 0.25 µg/mL). Fluconazole MICs ranged from 0.25 to 8 µg/mL, with MIC50 and MIC90 values of 1 and 4 µg/mL, respectively. Ketoconazole exhibited a MIC range of 0.12–0.5 µg/mL (MIC50 = 0.25 µg/mL; MIC90 = 0.5 µg/mL). Amphotericin B MICs ranged from 0.25 to 1 µg/mL, with MIC50 and MIC90 values of 0.5 and 1 µg/mL, and all isolates remained within the susceptible range per CLSI guidelines. Table 4Antifungal susceptibility profiles, enzymatic activities, and FKS1 gene results of the tested isolatesC. albicans (isolate No.)CASITRVORFLUKTZAmpBFKS1PhospholipasePz valuesProteinasePz values1SRSSSDDR+0.3+++0.2+++2SRRRRR+0.65+++0.85++3RRRRRR+0.74++1.1-4SRRRRR+0.72++0.72++5RRSRRR+0.11+++0.9+6SRRRRR+0.86++1.1-7SRRRRSDD+0.77++0.85++8SRRRRR+0.82++1.1-9SRSRRR+1.12-0.86++10SRRRRS+0.72++0.61+++11SRRRRSDD+0.7++0.78++12SRRRRSDD+0.72++0.84++13SRRRRR+0.68+++0.79++14SRRSRSDD+0.78++0.8++15SRRRRSDD+0.68+++0.84++16SRRRRSDD+0.6+++0.56+++17SSRSSR+0.72++0.92+18SSSSSSDD+0.75++0.82++19SRRRRS+0.69+++0.85++20SRRRRR+0.72++0.72++21SRSRRS+1.0-0.17+++22SRRRRSDD+0.34+++0.72++23SRRRRS+0.72++0.86++24SRRSSR+0.7++0.84++25SRRRRR+0.68+++1.12-26SRSRRS+0.72++0.84++27SRRSRSDD+0.75++0.8++28RSRRRR+0.15+++1.4-29SRRRRSDD+1.24-0.96+30SRRSRR+0.89++1.13-31SRRSSSDD+0.76++0.37+++32SRRRRS+0.2+++0.6+++33RRRRRR+0.34+++0.92+34SRRRRS+0.7++0.85++35RRRRRSDD+0.93+1.1-36SRRRRR+0.7++0.84++37RRRRRR+0.92+0.45+++38SRRRRS+0.75++0.79++39SRRRRSDD+0.7++0.84++40SRRRRSDD+0.6+++0.72++41SRRSRSDD+0.4+++0.9+42SRSSSSDD+0.83++1.18-43SSRSRSDD+0.7++0.82++44SSSSDDSDDSDD+0.75++0.88++45SSSSSSDD+0.84++0.92+46SSRSSSDD+0.7++0.85++47SSSSSSDD+0.0+++0.84++48SSSSSSDD+0.7++0.98+49SRRSDDSDDSDD+0.72++0.85++50SRRRRSDD+0.84++0.73++CAS, Caspofungin; ITR, Itraconazole; VOR, Voriconazole; FLU, Fluconazole; KTZ, Ketoconazole; AmpB, Amphotericin B; S, susceptible; R, resistant; SDD, susceptible dose dependent; FKS1 (+: present, -: absent); Phospholipase and Proteinase enzyme activities reported as strong (+++), moderate (++), weak (+), or no activity (-) Antifungal susceptibility profiles, enzymatic activities, and FKS1 gene results of the tested isolates CAS, Caspofungin; ITR, Itraconazole; VOR, Voriconazole; FLU, Fluconazole; KTZ, Ketoconazole; AmpB, Amphotericin B; S, susceptible; R, resistant; SDD, susceptible dose dependent; FKS1 (+: present, -: absent); Phospholipase and Proteinase enzyme activities reported as strong (+++), moderate (++), weak (+), or no activity (-) Virulence-associated enzymatic activities Phospholipase and proteinase activities were assessed in all 50 clinical C. albicans isolates. Based on categorical Pz values, phospholipase production was predominantly moderate (60%), with strong activity observed in 26% of isolates. Weak and negative activities were detected in 4% and 10% of isolates, respectively. Proteinase activity was most frequently moderate (58%), with strong activity in 14% of isolates, while weak and negative activities were each observed in 14% of isolates (Fig. 2). Quantification of phospholipase and proteinase activities in 50 clinical Candida albicans isolates. Each data point (circle) represents an individual isolate, with enzymatic activity categorized based on Pz values To provide a more detailed overview, continuous Pz values for each isolate are presented in Table 3. Phospholipase Pz values ranged from 0.61 to 1.00, with a mean of 0.78 ± 0.11. Proteinase Pz values ranged from 0.58 to 1.00, with a mean of 0.79 ± 0.13. These continuous data highlight the variability in enzymatic activity across isolates and allow more precise comparisons among strains, as well as potential correlations with antifungal susceptibility profiles and FKS1 expression levels. Detection and expression analysis of the FKS1 gene The presence of the FKS1 gene was confirmed in all C. albicans isolates by conventional PCR, with specific amplification products visualized on 1% agarose gel electrophoresis. Basal FKS1 transcript levels were subsequently assessed by real-time PCR using ACT1 as the endogenous reference gene. Relative expression values were calculated using the 2−ΔΔCt method and reflect normalized basal expression levels relative to ACT1, not fold induction relative to a separate calibrator strain. All measurements were derived from three technical replicates, and the observed expression values were low across all isolates, representing basal transcription rather than functional resistance. Among the isolates analyzed, isolate 8 exhibited the highest basal expression (2−ΔΔCt = 0.0415), whereas isolate 2 showed the lowest expression (2−ΔΔCt = 0.0007). Although statistical testing indicated differences between isolates, these results should be interpreted descriptively due to the small sample size and exploratory nature of the analysis. No direct correlation between basal FKS1 expression levels and phenotypic echinocandin resistance was observed. These data are presented in Fig. 3. Relative expression levels of the FKS1 gene in Candida albicans isolates Discussion This study integrated molecular identification, antifungal susceptibility profiling, virulence factor assessment, and gene expression analysis to better characterize clinical C. albicans isolates obtained from pediatric patients, including a subgroup of neonates. All isolates were confirmed as C. albicans through ITS region sequencing with strong phylogenetic support. Antifungal susceptibility testing demonstrated that caspofungin was the most active agent, with 88% of isolates classified as susceptible and 12% as resistant. Although some isolates exhibited higher amphotericin B MICs within the observed distribution, all isolates were categorized as susceptible according to current CLSI M27-A4 clinical breakpoints, supporting the continued clinical efficacy of amphotericin B. In contrast, azole susceptibility varied among isolates, with itraconazole and voriconazole showing higher proportions of non–wild-type isolates, while fluconazole and ketoconazole demonstrated moderate resistance. Collectively, these findings highlight the ongoing need for routine antifungal susceptibility surveillance in NICU settings, particularly for azole agents [21, 22]. These findings partially align with those of Mahmoudabadi et al., who identified C. albicans as the leading species in NICU and ICU settings and observed moderate fluconazole resistance, along with notable amphotericin B resistance [21]. Notably, their study reported amphotericin B resistance, whereas in our study, all isolates had amphotericin B MICs ≤ 1 µg/mL and were classified as susceptible, reinforcing the continued efficacy of this antifungal drug. Similarly, Sütçü et al. reported lower rates of fluconazole resistance and minimal caspofungin resistance, but variability across studies suggests that local epidemiological differences, patient populations, and treatment practices significantly influence resistance trends [22]. Mechanistic insights from prior studies further illuminate these findings. Arendrup et al. identified specific mutations in the FKS1 gene (particularly the S645P substitution) as responsible for echinocandin resistance, and noted that detection sensitivity may vary depending on the testing method employed [23]. This emphasizes the importance of incorporating molecular diagnostics alongside standardized testing protocols for reliable resistance assessment. In this study, FKS1 was detected in all isolates and exhibited variable basal expression levels by real-time PCR. The reported 2−ΔΔCt values represent normalized expression relative to ACT1 and do not indicate fold induction or functional resistance. Observed differences among isolates, including isolates 2, 7, and 8, should be interpreted descriptively due to the small sample size and exploratory design. Caspofungin MICs for these isolates remained within the susceptible range. The functional role of virulence factors in pathogenesis was also explored through enzymatic profiling. Approximately 14% of isolates demonstrated strong phospholipase and proteinase activity, suggesting the involvement of hydrolytic enzymes in neonatal infections, representing a subgroup within the pediatric population. These results are consistent with findings by Dabiri et al., who observed high enzymatic activity in C. albicans isolates, particularly in proteinase and phospholipase expression [24]. Oksuz et al. further demonstrated that although such enzyme activity is present in healthy individuals, it is more pronounced in clinical isolates, supporting the influence of host factors on pathogenic expression [25]. In contrast, Peremalo et al. highlighted species-specific differences, with C. rugosa and C. pararugosa exhibiting strong proteinase and esterase activity but lacking phospholipase activity altogether [26]. Such variation underscores the need for species- and strain-specific profiling when evaluating virulence potential, particularly given the emergence of multidrug-resistant non-albicans Candida species. Additionally, the observed variation in FKS1 expression among isolates supports the idea that resistance mechanisms in Candida are multifactorial. Studies by Yang et al. showed that even in the absence of direct FKS1 mutations, altered gene expression and chromosomal changes could lead to increased echinocandin tolerance [13]. Beattie et al. also demonstrated that modest reductions in FKS1 expression in Cryptococcus neoformans significantly affected fungal burden in vivo, despite minimal growth impact in vitro [27]. These findings highlight the clinical importance of transcriptional regulation, not just genetic mutation, in antifungal response. Zambrano et al. further emphasized the complexity of echinocandin action, showing that drug efficacy may not directly correlate with biofilm biomass or metabolic activity, particularly for caspofungin [28]. This complexity demands a more nuanced approach to evaluating antifungal performance in the context of varying resistance phenotypes. A limitation of the present study is that sequencing of FKS1 hotspot regions was not performed. Although expression analysis provides information on potential adaptive responses, molecular confirmation of hotspot mutations would provide stronger evidence regarding echinocandin resistance mechanisms. Additionally, other echinocandin agents, such as micafungin and anidulafungin, were not included in the antifungal susceptibility testing panel due to limited availability in our laboratory. This omission should be considered when interpreting the generalizability of echinocandin susceptibility results. Future studies should integrate both expression profiling and gene sequencing, as well as a broader panel of echinocandins, to more comprehensively assess the functional role of FKS1 in neonatal isolates. Conclusion This study provides a detailed molecular and phenotypic characterization of C. albicans isolates from pediatric patients, with subgroup-level observations in neonates and young infants. C. albicans was confirmed as the predominant species, with variable azole resistance and enzymatic virulence profiles. No phenotypic echinocandin resistance or tolerance assays were performed, and differential FKS1 expression should be interpreted cautiously as preliminary observational data rather than evidence of echinocandin tolerance. The presence of proteinase and phospholipase activity in a subset of isolates underscores their potential role in pathogenesis. These findings highlight the value of combined molecular and phenotypic analyses for guiding antifungal therapy and infection management in neonatal populations, while emphasizing the need for further studies incorporating genomic analyses to better understand resistance mechanisms. Acknowledgements The authors appreciate Mahdis Yousefi, Department of Mycology at Pasteur Institute of Iran for her kind assistance in gene expression analysis by Real-time PCR. Abbreviations 1, 3-beta-glucan synthase Candida albicans Polymerase chain reaction Clinical laboratory standards institute Actin gene Minimum inhibitory concentration Sabouraud dextrose agar Neonatal intensive care unit Caspofungin Itraconazole Voriconazole Fluconazole Ketoconazole Amphotericin B Author contributions Mandada Rezaei-Mojaz & Hanie Hajghafari: Writing - original draft, Investigation, Conceptualization, Methodology, Software, Formal analysis, Writing - Review and Editing. Masoomeh Shams-Ghahfarokhi: Validation, Conceptualization, Writing - Review and Editing. Simasadat Seyedjavadi: Methodology, Software, Formal Analysis, Writing - Review and Editing. Zahra Salehi: Validation, Conceptualization, Writing - Review and Editing. Ali Eslamifar: Resources, Writing, Review and Editing. Fatemehsadat Jamzivar: Methodology, Formal Analysis, Writing - Review and Editing. Mehdi Razzaghi-Abyaneh: Conceptualization, Funding Acquisition, Project Administration, Formal analysis, Supervision, Writing - Review and Editing. Funding The study was not funded, not supported by any grant. No grant award is available. Data availability The datasets generated and/or analyzed during the current study are available in the National Center for Biotechnology Information (NCBI) [Gene Bank accession numbers: PX467504, PX467506, PX470696, PX470697, PX470699, PX470707, PX482402, PX482403 and PX482404]. Declarations Ethics approval and consent to participate The study received ethical approval from the Ethics Committee of Tehran Medical Sciences Islamic Azad University, Tehran, Iran (Approval No. IR.IAU.PS.332). Written informed consent was obtained from all participants or their legal representatives. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Mandana Rezaei-Mojaz and Hanie Hajghafari contributed equally to this work and should be considered co-first authors. References Associated Data Data Availability Statement The datasets generated and/or analyzed during the current study are available in the National Center for Biotechnology Information (NCBI) [Gene Bank accession numbers: PX467504, PX467506, PX470696, PX470697, PX470699, PX470707, PX482402, PX482403 and PX482404].